Business
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH) The
About this update from Spruce Biosciences, Inc.
[{"type":"text","content":"\nPresentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia (CAH)\n\n\nThe company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a poster presentation\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nSpruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia (CAH) will be presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.\n\n\nIn addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CAH, as an illustration of outcomes of current pediatric CAH disease management, was accepted for poster presentation at the PES conference.\n\n\nPES 2024 Poster Presentation Details:\n\n\nTitle: Baseline Characteristics of CAHptain: A Phase 2 Dose-finding Study of Tildacerfont in Children with Classic Congenital Adrenal Hyperplasia\nAbstract Number: 6899\nPoster Session: 2\nSession Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT\nPresenter: Mimi S. Kim, M.D., Co-Director, Congenital Adrenal Hyperplasia Comprehensive Care Clinic, Children’s Hospital Los Angeles\n\n\nTitle: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia\nAbstract Number: 6898\nPoster Session: 2\nSession Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT\nPresenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence\n\n\nThe poster presentations will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.\n\n\nAbout Spruce Biosciences\n\n\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializi...